Market Place
Sourcing Support
All News #Library
Biotech
Ocular Therapeutix To Release Q1 2026 Financial Results On May 5
28 Apr 2026 //
GLOBENEWSWIRE
Ocular Therapeutix To Host Investor Day On June 17, 2026
22 Apr 2026 //
GLOBENEWSWIRE
Ocular Therapeutix Issues Inducement Grants Under Nasdaq Rules
14 Apr 2026 //
GLOBENEWSWIRE
Ocular Therapeutix™ to Present Additional SOL-1 Data in April
01 Apr 2026 //
GLOBENEWSWIRE
Ocular Therapeutix To Unveil SOL-1 Data At Macula Society
23 Feb 2026 //
GLOBENEWSWIRE
Ocular`s Hydrogel Outperforms Regeneron`s Eylea In Wet AMD
17 Feb 2026 //
BIOSPACE
Ocular`s Ophthalmologic Version of Inlyta bests Eylea in ph. 3
17 Feb 2026 //
FIERCE PHARMA
Ocular Therapeutix To Unveil SOL-1 Phase 3 Wet AMD Trial Results
13 Feb 2026 //
GLOBENEWSWIRE
Ocular Therapeutix Reports Q4, FY 2025 Results & Highlights
05 Feb 2026 //
GLOBENEWSWIRE
Ocular Therapeutix Names Robinson Global as CCO
21 Jan 2026 //
GLOBENEWSWIRE
Ocular Therapeutix Speeds Up AXPAXLI NDA Timeline For Wet AMD
08 Dec 2025 //
GLOBENEWSWIRE
Ocular Therapeutix Grants Inducement Under Nasdaq Rule 5635(c)(4)
05 Dec 2025 //
GLOBENEWSWIRE
Ocular Therapeutix Initiate 1st Patient Randomization in HELIOS-3
24 Nov 2025 //
GLOBENEWSWIRE
Ocular Therapeutix Unveils Q3 2025 Financials & Business Update
04 Nov 2025 //
GLOBENEWSWIRE
Ocular Therapeutix To Release Q3 2025 Financial Results On Nov 4
28 Oct 2025 //
GLOBENEWSWIRE
Ocular Therapeutix™ Set to Announce Q2 2025 Financial Results
29 Jul 2025 //
GLOBENEWSWIRE
Regeneron buys London-based ocular biotech
03 Jan 2025 //
ENDPTS
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.